Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Ligand’s Fourth Quarter Financial Results to be Reported February 3rd
Ligand Receives Milestone Payment from Merck
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies
Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients
Ligand Reports Third Quarter 2020 Financial Results
Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment
Ligand Provides Highlights from Today’s Investor Day Event
Ligand’s Third Quarter Financial Results to be Reported October 30th
Ligand to Divest Vernalis Research Operations
Ligand to Host Virtual Investor Day on October 20th
Ligand Completes Acquisition of Pfenex Inc.
Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.
